Delving into the Latest Updates on Prilocaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(Propylamino)-o-propionotoluidide, 2-Methyl-alpha-propylaminopropionanilide, alpha-n-Propylamino-2-methylpropionanilide

+ [14]

Target

SCNA x VDCCs

Mechanism

SCNA modulators(Sodium channel alpha subunit modulators), VDCCs modulators(Voltage-gated calcium channel modulators)

Therapeutic Areas

Urogenital Diseases

Active Indication

Hyperemesis Gravidarum

Inactive Indication

Anesthesia

Originator Organization

AstraZeneca PLC

Active Organization

Hubei Jumpcan Pharmaceutical Co., Ltd.

Inactive Organization

AstraZeneca LP

Drug Highest PhaseApproved

First Approval Date

US (18 Nov 1965),

Anesthesia

Regulation-

Login to view timeline

Structure

Molecular FormulaC13H21ClN2O

InChIKeyBJPJNTKRKALCPP-UHFFFAOYSA-N

CAS Registry1786-81-8

The goal of this randomised trial is to use a short acting local anaesthetic drug (hyperbaric prilocaine 2%) which is beneficial in short operations which are performed as a day case surgery.
in this study the investigators will use 3 different doses of prilocaine 2% (40,50 or 60 mg ) intrathecal (in spinal anaesthesia) in participants undergoing arthroscopy on the knee.
the primary outcome is to compare time to micturate (go to the bathroom) between the three groups .
the secondary outcomes are:
* time to recovery of the motor and sensory block
* time to discharge from post anesthesia care unit
* any complications ; itching, lowered blood pressure, nausea and vomiting.

Start Date30 Nov 2024

Sponsor / Collaborator

Cairo University

NCT06680167 / Active, not recruitingEarly Phase 1IIT

A Comparative Study Between Hyperbaric Prilocaine 2% Versus Hyperbaric Bupivacaine 0.5% For Intrathecal Anesthesia in Caesarean Section

Comparison between effects of hyperbaric bupivacaine 0.5% vs Hyperbaric prilocaine 2% in spinal anesthesia of women undergoing elective caesarean section such as onset time of sensory and motor block, duration of sensory and motor block, effects of maternal hemodynamics and expected side effects .

Start Date09 Oct 2024

Sponsor / Collaborator

Sohag University

CTRI/2024/09/073516 / RecruitingPhase 4IIT

Efficacy & safety of topical Lidocaine and Prilocaine gel for arteriovenous fistula cannulation pain in hemodialysis patients A Crossover Randomized Control Trial - NIL

Start Date24 Sep 2024

Sponsor / Collaborator

Manipal college of Medical Sciences

100 Clinical Results associated with Prilocaine Hydrochloride

Login to view more data

100 Translational Medicine associated with Prilocaine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Prilocaine Hydrochloride

Login to view more data

1,878

Literatures (Medical) associated with Prilocaine Hydrochloride

01 Dec 2024·Journal of Cosmetic Dermatology

Evaluating the efficacy of local anesthetic techniques during scalp microneedling

Article

Author: Bergler‐Czop, Beata ; Leonik, Szymon ; Smoczok, Michał

Abstract:

Introduction:

An increasing interest in minimally invasive procedures hassled to a demand for an effective local anesthetic algorithm. The scalp presents a challenge in achieving effective anesthesia due to the presence of hair shafts. This study aims to evaluate the efficacy of different methods during a microneedling procedure, including 25 mg lidocaine and 25 mg prilocaine cream, skin spray with 10% lidocaine, and cold gel compresses.

Materials and Methods:

Sixty‐two men aged between 20 and 50 years underwent three microneedling treatments, each using a different method of anesthesia. The treatment area was divided into two equal parts, with one part exposed to a specific anesthetic method. Patients were asked to rate their pain on a 0–10 verbal analog scale. An attempt was made to objectify the results using algometry.

Results:

A negative correlation was observed between the algometry results and the VAS score after the application of the cream and cold compresses.

Discussion:

When choosing monotherapy, it is recommended to use cold gel compresses for scalp microneedling after considering the advantages and disadvantages of different methods.

02 Nov 2024·MUTAGENESIS

Impact of DNA ligase inhibition on the nick sealing of polβ nucleotide insertion products at the downstream steps of base excision repair pathway

Article

Author: Almohdar, Danah ; Huang, Shuang ; Calbay, Ozlem ; Kamble, Pradnya ; Narayan, Satya ; Basavannacharya, Chandrakala ; Gulkis, Mitchell ; Çağlayan, Melike

Abstract:

DNA ligase (LIG) I and IIIα finalize base excision repair (BER) by sealing a nick product after nucleotide insertion by DNA polymerase (pol) β at the downstream steps. We previously demonstrated that a functional interplay between polβ and BER ligases is critical for efficient repair, and polβ mismatch or oxidized nucleotide insertions confound the final ligation step. Yet, how targeting downstream enzymes with small molecule inhibitors could affect this coordination remains unknown. Here, we report that DNA ligase inhibitors, L67 and L82-G17, slightly enhance hypersensitivity to oxidative stress-inducing agent, KBrO3, in polβ+/+ cells more than polβ-/- null cells. We showed less efficient ligation after polβ nucleotide insertions in the presence of the DNA ligase inhibitors. Furthermore, the mutations at the ligase inhibitor binding sites (G448, R451, A455) of LIG1 significantly affect nick DNA binding affinity and nick sealing efficiency. Finally, our results demonstrated that the BER ligases seal a gap repair intermediate by the effect of polβ inhibitor that diminishes gap filling activity. Overall, our results contribute to understand how the BER inhibitors against downstream enzymes, polβ, LIG1, and LIGIIIα, could impact the efficiency of gap filling and subsequent nick sealing at the final steps leading to the formation of deleterious repair intermediates.

30 Sep 2024·Acta odontologica latinoamericana : AOL

Changes in masseter muscle structure, membrane lipid peroxidation and Ca-ATPase activity as effects of different local anesthetics.

Article

Author: de la Cal, Carolina ; Di Croce, Daniel E ; Takara, Delia

Local anesthetics (LA) can cause undesired effects such as sustained contraction of skeletal muscles as a result of structural and functional changes. Proper skeletal muscle function is controlled by intracellular Ca2+ concentration and efficient energy (ATP) production, which is closely related to cell ultrastructure. Aim: The aim of this study was to identify the structural and functional changes caused by LAs. Materials and Method: Male Wistar rats weighing 200 to 250g were used (n:49). They were divided into seven groups. One group was not anesthetized or treated (Control). The other six groups underwent intramuscular (IM) anesthesia with xylazine 2% (0.05 ml) and ketamine 50 mg/ml (0.1 ml/100g rat weight), and one of the following was applied to the masseter muscle (MM): no further treatment (Anesthetic Control group, CA); 0.1ml physiological saline solution (group SF); Carrageenin (group Carr) 1% as positive control group; prilocaine (group Pri), mepivacaine (group Mepi); or articaine (group Arti) 0.3M, IM. The animals were euthanized by cervical dislocation one hour after treatment. The effects of the different anesthetics on the MM were evaluated histologically and by electronic microscopy (EM). Ca-ATPase and membrane lipid peroxidation (LPX) were evaluated in muscle homogenates under the same conditions as those used to prepare the histological sections. Results: In general, structural damage and increased muscle contraction were observed in tissues treated with anesthetics. The most extreme values of Ca-ATPase activity and LPX were observed in the positive control group (carrageenin). Results were analyzed by one-way ANOVA for multiple comparisons and Tukey's test (p < 0.05). Conclusions: The results suggest that in the short term, local anesthetics affect the muscle function and are associated to structural changes.

2

News (Medical) associated with Prilocaine Hydrochloride

07 Nov 2023

·www.prnewswire.com

Advanced Anesthesia Devices and Ambulatory Surgical Centers Propel Growth in the US Anesthesia Market

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more. Market Segmentation The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region. Types and Products In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment. When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market. The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures. Key Drivers and Challenges Driver: Increase in Monitored Anesthesia Use The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs. Challenge: Side Effects of Anesthesia While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market. Trend: Growth of Ambulatory Surgical Centers (ASC) The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices. COVID-19 Analysis The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased. Key Players The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company. Top Impacting Factors Growth Drivers Rising Geriatric Population Growing Healthcare Expenditure Increase in Monitored Anesthesia Use Increase In Number Of Approval For Anesthesia Drugs Challenges Side Effects of Anesthesia Lack of Skilled Anesthesiologist Trends Escalating Establishment of Ambulatory Surgical Centers (ASC) Technological Enhancement of Anesthesia Devices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

18 Nov 2022

·www.prnewswire.com

US Anesthesia Drugs and Devices Market to Reach $8.88 Billion by 2027

DUBLIN, Nov. 18, 2022 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come. Market Segmentation Analysis: By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region. By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period. By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market. By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures. Market Dynamics: Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population. Steady growth in aging population raised the incidence of the chronic condition over the past decade. This had caused increasing number of surgical procedures of elderly patients. Additionally, benefits such as advances in surgery and anesthesia can improve function and quality of life for older patients also supported market growth. Thus, the positive acceleration in aging population consequently supported the growth of the anesthesia drugs and devices market in the US. Furthermore, the market has been growing over the past few years, due to factors such as growing healthcare expenditure, increase in monitored anesthesia use, increase in number of approval for anesthesia drugs and many other factors. Challenges: However, the market has been confronted with some challenges specifically, lack of skilled anesthesiologist, etc. - Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as the escalating establishment of ambulatory surgical centers (ASC), technological enhancement of anesthesia devices, etc. Technology upgradation such as Closed loop TIVA and Ultrasound-Guided Regional Anesthesia (UGRA) are expected to propel the US drug and devices market during forecasted years. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Impact of COVID-19 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles Companies Mentioned KKR & Co. Inc. (Envision Healthcare Corporation) Baxter International Inc. Blackstone (TeamHealth) Becton, Dickinson and Company Braun (B. Braun Avitum AG) 3M Company Abbvie Inc. Teleflex Incorporated Dragerwerk AG & Co. KGaA AstraZeneca Plc Abbott Laboratories General Electric Company ICU Medical, Inc SunMed LLC For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Prilocaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01243	Prilocaine Hydrochloride	N01BB04	DB00750

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	CN	Hubei Jumpcan Pharmaceutical Co., Ltd.	13 Feb 2006
Anesthesia	US	AstraZeneca LP	18 Nov 1965

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2024	Not Applicable	Premature Ejaculation	-	Dapoxetine 30 mg+mirodenafil 50 mg	scmfbryvny(snetmlvvbl) = rxnghgmpgv ntclqxxjge (ylvjgfdvuv, 23.0 - 400.0)	Positive	01 May 2024
				OLNP-05	scmfbryvny(snetmlvvbl) = penkcmpzgo ntclqxxjge (ylvjgfdvuv, 140.0 - 410.0)
NCT02973048 (not provided, Pubmed \| Eur J Anaesthesiol)	Phase 3	-	40	Hyperbaric prilocaine 50mg	mpmmzddupn(xafpnpwlsa) = reteljrzis pbzfpcvsgb (ypssgbhppb ) View more	Positive	18 May 2021
				Hyperbaric bupivacaine 10mg	mpmmzddupn(xafpnpwlsa) = ivswvxlmsg pbzfpcvsgb (ypssgbhppb ) View more
Pubmed \| Anaesthesia	Not Applicable	-	50	Hyperbaric prilocaine	efuphmsceu(oydvszbyfv) = npgdscnokt izafoiiuzb (vjjhhwnvpm )	-	11 Jan 2021
				Hyperbaric bupivacaine	efuphmsceu(oydvszbyfv) = khbvxvnpcv izafoiiuzb (vjjhhwnvpm )
NCT02973048 (not provided, CTgov)	Phase 3	Pain \| Hypotension	40	Hyperbaric bupivacaine (Hyperbaric Bupivacaine)	qgqkldqntp(qsgtrfrqar) = iyvtzvsxuz twsdscoevw (rhkqulvlrf, gnwhsbaldt - nedwvlfsjp) View more	-	02 Jul 2020
				Hyperbaric prilocaine (Hyperbaric Prilocaine)	qgqkldqntp(qsgtrfrqar) = mazlggnaei twsdscoevw (rhkqulvlrf, qyggkzfxno - jguinaopsd) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	udaumgtkke(immtzfzhpj) = jekcdrkdgi mxkvsdgttq (oxunyiuipi, dfgipgzlmc - pzohdespty) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	udaumgtkke(immtzfzhpj) = kdtmdcjeqy mxkvsdgttq (oxunyiuipi, viruyhyujx - jcadbgbpsb) View more
NCT05649020 (Pubmed \| Anaesth Crit Care Pain Med)	Phase 4	-	-	Chloroprocaine	vvwkcglaeu(agiewuuhaj) = spmckfspwd uaqimrrpqv (xwcaewunad )	-	01 Dec 2016
NCT00556478 (CTgov)	Phase 2/3	Premature Ejaculation	256	prilocaine+PSD502, contains a mixture of lidocaine (Double-Blind Active)	yjkzxwnmqf(obhesqacwe) = nvhycuhcmv pnzsdrtgpn (xvrzorrwzp, leopwcyedx - jjlelrtiyn) View more	-	26 Sep 2016
				Placebo (Double-Blind Placebo)	yjkzxwnmqf(obhesqacwe) = frtbixslbl pnzsdrtgpn (xvrzorrwzp, qgewtqkftk - iegszeokvp) View more
NCT02336958 (CTgov)	Not Applicable	Carotid Stenosis	40	intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Ropivacaine)	ahvkfjnzai(kuctgymtjl) = rabalqrkaf czixzoqbyd (fsymmjwtuk, ojyjoazwsh - qeontidftq) View more	-	23 Mar 2015
				pericarotidal infiltration (placebo comparator) saline+intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Saline)	ahvkfjnzai(kuctgymtjl) = ohvnccallk czixzoqbyd (fsymmjwtuk, doujkfeumx - miqxfqvtrj) View more
NCT01643616 (CTgov)	Not Applicable	-	250	ultrasound guidance+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group US)	lmkctgmuip(lyxmgrkxja) = ikebqanddb abndbicpeg (txxrvxrhrq, odmvoemdhj - iuupojpnnm) View more	-	01 Nov 2013
				nerve stimulation technique+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group NS)	lmkctgmuip(lyxmgrkxja) = ilwyazcjcw abndbicpeg (txxrvxrhrq, hpqomamowc - ugktveztoh) View more
NCT01309360 (CTgov)	Phase 4	-	120	prilocaine 1%+midazolam (Group A : 40ml Prilocaine 1%)	jbzrqunsfw(hqkipqtbna) = quejtmnmui nrmgmquxhu (gticbxgnam, zyjqbowvxm - dwssgyuczn) View more	-	27 Jun 2011
				prilocaine 1%+midazolam (Group B : 30ml Prilocaine 1%)	jbzrqunsfw(hqkipqtbna) = kpmdnhgtvp nrmgmquxhu (gticbxgnam, syyqgclvkq - cagcvyvtii) View more